** Shares of weight-loss drug developer of Veru VERU.O rise 46% to 74 cents premarket
** VERU says combination of its experimental drug, enobosarm, and semaglutide resulted in fewer gastrointestinal side effects such as diarrhea and nausea in mid-stage trial, compared with semaglutide alone
** Combo drug met main goal of mid-stage trial earlier this year
** Patients taking enobosarm 3mg with semaglutide saw 99% loss of fat while preserving lean muscle mass, co says
** VERU has requested meeting with U.S. FDA to discuss next steps for enobosarm, including potential late-stage trial
** As of last close, stock down 21.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.